Clinical trials: Prostatic Adenocarcinoma
Prostate Cancer, Prostate Adenocarcinoma
Using Tissue-based Spatial Data to Understand How Obesity-related Tumor Metabolites Fuel Prostate Cancer Progression
Evaluate the protein expression of lactate dehydrogenase enzyme (LDHA) and MCT-1/-4 transporters, involved in lactate synthesis and transport, in prostate carcinoma tissues from severely overweight/obese (BMI > 27.5) and…
- Conditions
- Prostate Cancer, Prostate Adenocarcinoma, Prostate Neoplasm, Prostatic Neoplasm
- Trial name
- OBESITA'&PCa (NCT06292897)
- Testing
- observational study
- Where
- Italy
- Volunteers
- 25 people
- Sponsor
- Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Prostate Cancer
Beta Adrenergic Receptor Blockade as a Novel Therapy for Patients With Adenocarcinoma of the Prostate
This will be a single arm, window of opportunity study in men with treatment-naïve prostate cancer who will proceed to prostatectomy. Men will be treated with carvedilol prior to undergoing prostatectomy.
- Trial name
- NCT02944201
- Testing
- Carvedilol
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Montefiore Medical Center
Prostate Cancer
Brachytherapy in Treating Patients With Prostate Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Giving radiation therapy through seeds implanted into the prostate may kill more tumor cells.
- Trial name
- NCT00003312
- Testing
- iodine I 125
- Where
- 258 sites in United States, Canada
- Volunteers
- 95 people
- Sponsor
- Radiation Therapy Oncology Group
Prostate Cancer
WALNUTS for POWER: Polyphenols, Omega-3 Fatty Acids, Weight Loss, and EneRgy
This is a randomized control trial testing the effect of walnut supplementation on prostate cancer progression in 50 men with biopsy confirmed prostate cancer and planning to undergo RP.
- Trial name
- NCT03824652
- Testing
- walnuts, usual diet, phone counseling with dietitian
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- Stephen Freedland
Prostate Cancer
GTI-2040, Docetaxel, and Prednisone in Treating Patients With Prostate Cancer
RATIONALE: GTI-2040 may stop the growth of tumor cells by blocking the enzymes necessary for their growth. Drugs used in chemotherapy, such as docetaxel, work in different ways to stop tumor cells from dividing so they stop…
- Trial name
- NCT00087165
- Testing
- GTI-2040, docetaxel, prednisone
- Where
- 5 sites in Canada
- Volunteers
- 22 people
- Sponsor
- University Health Network, Toronto
Adenocarcinoma of the Prostate
Hypofractionated Image-Guided Radiotherapy (IGRT) With Organ Motion Mitigation and Urethral Sparing for Prostate Cancer
The present study evaluates the safety, feasibility, quality-of-life effects, PSA kinetics, and clinical outcomes of definitive dose-escalated external beam radiotherapy for localized adenocarcinoma of the prostate.
- Trial name
- NCT02761889
- Testing
- Ultra-hypofractionated IGRT-VMAT with organ-motion mitigation and urethral sparing, Rectal balloon with air filling, Urethral catheter loaded with beacon transponders
- Where
- Portugal
- Volunteers
- 444 people
- Sponsor
- Fundacao Champalimaud
Adenocarcinoma of the Prostate, Prostate Cancer
Diindolylmethane in Treating Patients Undergoing Surgery for Stage I or Stage II Prostate Cancer
Giving diindolylmethane, a substance found in cruciferous vegetables, may help doctors learn more about how diindolylmethane is used by the body.
- Conditions
- Adenocarcinoma of the Prostate, Prostate Cancer, Stage I Prostate Cancer, Stage II Prostate Cancer
- Trial name
- NCT00450229
- Testing
- diindolylmethane, therapeutic conventional surgery, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- National Cancer Institute (NCI)
Prostate Cancer
Radiation Therapy With or Without Antiandrogen Therapy in Treating Patients With Stage I or Stage II Prostate Cancer
RATIONALE: Radiation therapy (RT) uses high-energy x-rays to damage tumor cells. Androgens can stimulate the growth of prostate cancer cells.
- Trial name
- NCT00002597
- Testing
- flutamide, Zoladex, Lupron
- Where
- 239 sites in United States, Canada
- Volunteers
- 2,028 people
- Sponsor
- Radiation Therapy Oncology Group
Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma
Abemaciclib Before 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer
This phase I/II trial tests the safety, side effects, and best dose of abemaciclib and whether it works before 177Lu-PSMA-617 in treating patients with castration resistant prostate cancer that has spread to other places in the…
- Conditions
- Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8
- Trial name
- UPLIFT (NCT05113537)
- Testing
- Abemaciclib, Lutetium Lu 177-PSMA-617
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Vadim S Koshkin
Adenocarcinoma of the Prostate
Pilot Study of 18F-DCFPyL PET/CT in the Evaluation of Men With an Elevated PSA Following Radical Prostatectomy
This pilot study aims to investigate the diagnostic utility of 18F-DCFPyL, a novel low-molecular weight PSMA PET/CT imaging agent, in men with an elevated PSA following radical prostatectomy.
- Trial name
- NCT02523924
- Testing
- 18F-DCFPyL
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Prostate Cancer
High-Intensity Focused Ultrasound Therapy in Treating Patients With Localized Prostate Cancer
RATIONALE: High-intensity focused ultrasound energy may be able to kill tumor cells by heating them without affecting normal tissue.
- Trial name
- NCT00561262
- Testing
- questionnaire administration, high-intensity focused ultrasound ablation, quality-of-life assessment
- Where
- United Kingdom
- Volunteers
- 60 people
- Sponsor
- University College London Hospitals
Metastatic Prostate Adenocarcinoma, Oligometastatic Prostate Carcinoma
A Study To Evaluate Hypofractionated Proton Therapy Or IMRT For Recurrent, Oligometastatic Prostate Cancer
This phase II trial studies the side effects of radiation therapy [hypofractionated proton beam radiation therapy (PBRT) or intensity-modulated radiation therapy (IMRT)] for the treatment of prostate cancer that has come back…
- Conditions
- Metastatic Prostate Adenocarcinoma, Oligometastatic Prostate Carcinoma, Prostate Adenocarcinoma, Recurrent Prostate Carcinoma
- Trial name
- NCT04190446
- Testing
- Intensity-Modulated Radiation Therapy, Proton Beam Radiation Therapy, Quality-of-Life Assessment
- Where
- United States
- Volunteers
- 84 people
- Sponsor
- Mayo Clinic
Prostate Adenocarcinoma, Recurrent Prostate Carcinoma
Gallium Ga 68-labeled PSMA-11 PET/CT in Detecting Recurrent Prostate Cancer in Patients After Initial Therapy
This clinical trial studies how well gallium Ga 68-labeled prostate-specific membrane antigen (PSMA)-11 positron emission tomography (PET)/computed tomography (CT) works in detecting prostate cancer that has come back (recurrent)…
- Trial name
- NCT02940262
- Testing
- Gallium Ga 68 Gozetotide, Laboratory Biomarker Analysis, Positron Emission Tomography
- Where
- United States
- Volunteers
- 1,138 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Non-small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck
A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies
This is a Phase 1, open-label, dose-escalation and dose-expansion study to evaluate the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD) and clinical activity of etrumadenant (AB928) in combination with…
- Conditions
- Non-small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck, Breast Cancer, Colorectal Cancer
- Trial name
- NCT03629756
- Testing
- Etrumadenant, Zimberelimab
- Where
- 15 sites in United States, Australia
- Volunteers
- 48 people
- Sponsor
- Arcus Biosciences, Inc.
Prostate Cancer
Genetic Analysis of Hereditary Prostate Cancer
Molecular approaches to the understanding of human neoplastic disease have revealed that multiple genetic alterations are an essential component of tumorigenesis.
- Trial name
- NCT00001469
- Where
- 8 sites in United States, Finland
- Volunteers
- 7,776 people
- Sponsor
- National Human Genome Research Institute (NHGRI)
Anaplastic Astrocytoma, Anaplastic Oligoastrocytoma
Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors
This phase I trial studies the side effects and best schedule of vaccine therapy with or without sirolimus in treating patients with cancer-testis antigen (NY-ESO-1) expressing solid tumors.
- Conditions
- Anaplastic Astrocytoma, Anaplastic Oligoastrocytoma, Anaplastic Oligodendroglioma, Estrogen Receptor Negative
- Trial name
- NCT01522820
- Testing
- DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Laboratory Biomarker Analysis, Pharmacological Study
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Roswell Park Cancer Institute
Prostate Cancer, Non-metastatic Prostate Cancer
Comparative Health Research Outcomes of NOvel Surgery in Prostate Cancer
Men diagnosed with significant cancer confined to the prostate currently undergo radical therapy directed to the whole prostate (radiotherapy or prostatectomy).
- Conditions
- Prostate Cancer, Non-metastatic Prostate Cancer, Prostate Adenocarcinoma
- Trial name
- IP4-CHRONOS (NCT04049747)
- Testing
- Radical therapy (radiotherapy or prostatectomy [radiotherapy can be external beam or brachytherapy], Focal therapy, Focal therapy after Finasteride 5Mg tablets for 12 weeks
- Where
- 10 sites in United Kingdom
- Volunteers
- 100 people
- Sponsor
- Imperial College London
Prostate Cancer, Prostate Adenocarcinoma
A Trial of Androgen Deprivation, Docetaxel, and Enzalutamide for Metastatic Prostate Cancer
This is a study with the combination of androgen deprivation therapy (ADT) and docetaxel with the addition of enzalutamide in the treatment of subjects with metastatic prostate cancer.
- Trial name
- NCT03246347
- Testing
- ADT+Docetaxel+Enzalutamide
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Wake Forest University Health Sciences
Advanced Solid Tumor, Advanced Cancer
A Study of MGC026 in Participants With Advanced Solid Tumors
The study is designed to understand the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary antitumor activity of vobramitamab tavatecan (MGC026) in participants with relapsed or refractory, unresectable…
- Conditions
- Advanced Solid Tumor, Advanced Cancer, Metastatic Cancer, Squamous Cell Carcinoma of Head and Neck
- Trial name
- NCT06242470
- Testing
- MGC026 Dose Escalation, MGC026 Dose for Expansion, Pembrollizumab
- Where
- 12 sites in United States, Australia and 1 more
- Volunteers
- 394 people
- Sponsor
- MacroGenics
Prostate Cancer, Adenocarcinoma of the Prostate
Bicalutamide and Raloxifene in Treating Patients With Metastatic or Hormone-Refractory Prostate Cancer
RATIONALE: Androgens can cause the growth of prostate cancer cells. Antihormone therapy, such as bicalutamide, may lessen the amount of androgens made by the body.
- Conditions
- Prostate Cancer, Adenocarcinoma of the Prostate, Hormone-resistant Prostate Cancer, Stage IV Prostate Cancer
- Trial name
- NCT01050842
- Testing
- bicalutamide, raloxifene, quality-of-life assessment
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Mayo Clinic
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.